Search

Displaying results 4851 - 4860 of 10000 in total
  1. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid … It also has an effect on viral gp160 envelope protein. [A31692]

  2. Drug

    7-Nitroindazole

    go.drugbank.com/drugs/DB02207
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    VGV-1

    go.drugbank.com/drugs/DB05328
    Experimental

    VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.

  4. Drug

    Canfosfamide

    go.drugbank.com/drugs/DB04972
    Investigational

    Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.

  5. Drug

    Neramexane

    go.drugbank.com/drugs/DB04926
    Investigational

    Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.

  6. Drug

    BCc1

    go.drugbank.com/drugs/DB16504
    Experimental

    BCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.

  7. Drug

    Avdoralimab

    go.drugbank.com/drugs/DB16392
    Investigational

    Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).

  8. Drug

    Cinitapride

    go.drugbank.com/drugs/DB08810
    Investigational

    Cinitapride is a gastroprokinetic agent and antiulcer benzamide with agonist activity at 5-HT1 and 5-HT4 receptors and antagonist activity at 5-HT2 receptors. It is marketed in Spain and Mexico.

    Synonyms: 4-Amino-N-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamide
  9. Drug

    Hydrocortisone aceponate

    go.drugbank.com/drugs/DB14538
    InvestigationalVet approved

  10. Drug

    IR501

    go.drugbank.com/drugs/DB06464
    Experimental

    It was last known to be in phase III clinical trials. … IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity.